October Pharma results, Q2 2025
Net profit, assets, equity and cash flow for Q2 2025, against the same period a year earlier, from the published financial statements.
Net profit35.49 millionEGP · −76.6% vs the same period a year earlier
In short
- October Pharma's net profit for Q2 2025 was about 35.49 million EGP, down −76.6% from 152 million EGP in Q2 2024.
Key lines against the same period a year earlier
This periodQ2 2024Change
Net profit35.49 million152 million−76.6%
Gross profit164 million546 million−70.0%
Total assets—1.41 billion—
Total liabilities—844 million—
Shareholders' equity—569 million—
Total liabilities and equity1.39 billion1.41 billion−1.8%
Operating cash flow—43.24 million—
Investing cash flow—-48.94 million—
Financing cash flow—12.94 million—
Net change in cash—7.23 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy